Abstract:BACKGROUND:Hepatocellular carcinoma (HCC) is an extensive heterogeneous disease where epigenetic factors contribute to its pathogenesis. Polycomb group (PcG) proteins are a group of subunits constituting various macro-molecular machines to regulate the epigenetic landscape, which contributes to cancer phenotype and has the potential to develop a molecular classification of HCC.RESULTS:Here, based on multi-omics data analysis of DNA methylation, mRNA expression, and copy number of PcG-related genes, we established an epigenetic classification system of HCC, which divides the HCC patients into two subgroups with significantly different outcomes. Comparing these two epigenetic subgroups, we identified different metabolic features, which were related to epigenetic regulation of polycomb-repressive complex 1/2 (PRC1/2). Furthermore, we experimentally proved that inhibition of PcG complexes enhanced the lipid metabolism and reduced the capacity of HCC cells against glucose shortage. In addition, we validated the low chemotherapy sensitivity of HCC in Group A and found inhibition of PRC1/2 promoted HCC cells' sensitivity to oxaliplatin in vitro and in vivo. Finally, we found that aberrant upregulation of CBX2 in Group A and upregulation of CBX2 were associated with poor prognosis in HCC patients. Furthermore, we found that manipulation of CBX2 affected the levels of H3K27me3 and H2AK119ub.CONTRIBUTIONS:Our study provided a novel molecular classification system based on PcG-related genes data and experimentally validated the biological features of HCC in two subgroups. Our founding supported the polycomb complex targeting strategy to inhibit HCC progression where CBX2 could be a feasible therapeutic target.

Polycomb Group Proteins and Their Roles in Carcinogenesis

Loss of the Polycomb group gene polyhomeotic induces non-autonomous cell overproliferation.

Polycomb Group (pcg) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications

Gene Silencing by the Polycomb Group Proteins and Associations with Cancer

Polycomb Directed Cell Fate Decisions in Development and Cancer

Polycomb genes and cancer: Time for clinical application?

The roles of Polycomb repressive complexes in mammalian development and cancer

Polycomb Repressor Complex: Its Function in Human Cancer and Therapeutic Target Strategy.

Polycomb Genes, Mirna, and Their Deregulation in B-cell Malignancies.

Polycomb Group Genes As the Key Regulators in Gene Silencing

The polycomb group proteins functions in epithelial to mesenchymal transition in lung cancer

LncRNA PCGEM1 in Human Cancers: Functions, Mechanisms and Promising Clinical Utility

Identification of Hepatocellular Carcinoma Subtypes Based on PcG-related Genes and Biological Relevance with Cancer Cells.

Epigenetic Silencing of Protocadherin 10 in Colorectal Cancer.

Genetic Alteration and Misexpression of Polycomb Group Genes in Hepatocellular Carcinoma.

Epigenetic regulation by polycomb group complexes: focus on roles of CBX proteins

Polycomb-Like Proteins in Gene Regulation and Cancer

Data from EZH2 Represses Target Genes through H3K27-Dependent and H3K27-Independent Mechanisms in Hepatocellular Carcinoma

One, Two, Three: Polycomb Proteins Hit All Dimensions of Gene Regulation

Epigenetic Regulation Mediated by Polycomb on Cellular Senescence

The Dynamic Interplay in Chromatin Remodeling Factors Polycomb and Trithorax Proteins in Response to DNA Damage